Legal & General Group Plc Sells 40,221 Shares of Qiagen N.V. $QGEN

Legal & General Group Plc cut its position in Qiagen N.V. (NYSE:QGEN) by 2.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,396,187 shares of the company’s stock after selling 40,221 shares during the period. Legal & General Group Plc’s holdings in Qiagen were worth $63,644,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Global Retirement Partners LLC raised its stake in shares of Qiagen by 279.9% in the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after buying an additional 851 shares during the period. Leonteq Securities AG bought a new stake in shares of Qiagen in the fourth quarter valued at $153,000. Banque Cantonale Vaudoise raised its stake in shares of Qiagen by 1.8% in the fourth quarter. Banque Cantonale Vaudoise now owns 16,363 shares of the company’s stock valued at $747,000 after buying an additional 290 shares during the period. North Dakota State Investment Board bought a new stake in shares of Qiagen in the fourth quarter valued at $340,000. Finally, Arbejdsmarkedets Tillaegspension bought a new stake in shares of Qiagen in the fourth quarter valued at $22,958,000. 70.00% of the stock is currently owned by institutional investors.

More Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen announced new research-use-only digital PCR assays to support Bundibugyo ebolavirus research and surveillance, highlighting continued product innovation and demand for its QIAcuity platform. QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak
• Positive Sentiment: One analysis said Qiagen’s margins, cash flow and debt-free balance sheet could help stabilize the investment case despite the weaker outlook, suggesting the company still has financial flexibility. Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?
• Neutral Sentiment: Another recent note outlined Qiagen’s 2026 growth drivers, including new launches, automation via Connect, and QIAstat-Dx menu expansion, but also acknowledged choppy demand conditions. QIAGEN Business Breakdown and Growth Drivers for 2026
• Neutral Sentiment: Zacks Research trimmed several future EPS estimates for Qiagen, but maintained a Hold rating, signaling caution rather than a major change in sentiment. Qiagen N.V. research updates
• Negative Sentiment: Qiagen cut its 2026 growth outlook after missing Q1 expectations, which is the main reason investors are selling the stock today. Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?
• Negative Sentiment: Pomerantz LLP launched an investor investigation into Qiagen, adding legal overhang and potentially increasing uncertainty for shareholders. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. – QGEN

Qiagen Price Performance

Qiagen stock opened at $36.62 on Friday. Qiagen N.V. has a 52 week low of $32.53 and a 52 week high of $57.81. The business has a 50-day simple moving average of $37.69 and a 200 day simple moving average of $44.75. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49. The stock has a market cap of $7.55 billion, a price-to-earnings ratio of 19.12, a PEG ratio of 3.64 and a beta of 0.64.

Qiagen (NYSE:QGEN) last posted its earnings results on Thursday, May 7th. The company reported $0.54 EPS for the quarter, hitting the consensus estimate of $0.54. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.The business had revenue of $492.32 million during the quarter, compared to analysts’ expectations of $496.15 million. During the same period in the previous year, the business earned $0.56 earnings per share. On average, research analysts forecast that Qiagen N.V. will post 2.43 earnings per share for the current fiscal year.

Qiagen Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th will be given a dividend of $0.35 per share. The ex-dividend date is Tuesday, July 7th. This is a positive change from Qiagen’s previous annual dividend of $0.26. This represents a yield of 104.0%. Qiagen’s dividend payout ratio (DPR) is presently 18.32%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. UBS Group set a $52.00 target price on Qiagen in a research note on Monday, February 9th. Zacks Research upgraded Qiagen from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 29th. Weiss Ratings cut Qiagen from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, May 12th. Stifel Nicolaus set a $36.00 price target on Qiagen and gave the company a “hold” rating in a research report on Monday, May 18th. Finally, Barclays set a $38.00 price target on Qiagen and gave the company an “equal weight” rating in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, Qiagen currently has an average rating of “Moderate Buy” and an average target price of $44.98.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.